Form 4: Lemaitre Vascular Inc. Executive Acquires Dividend Equivalent Rights
SEC Form 4 Filing
Trent G. Kamke, Senior VP of Operations at Lemaitre Vascular Inc., reports the acquisition of dividend equivalent rights related to restricted stock unit and performance share unit awards.
Summary
- On March 27, 2025, Trent G. Kamke, Senior VP of Operations at Lemaitre Vascular Inc., acquired dividend equivalent rights.
- These rights are associated with restricted stock unit (RSU) and performance share unit (PSU) awards granted between December 2020 and December 2024.
- The dividend equivalent rights vest proportionately with the underlying awards and are economically equivalent to shares of Lemaitre Vascular Inc.'s common stock.
- The acquired dividend equivalent rights are: 0.389, 0.7103, 1.446 (twice), 1.8542, 2.2225, and 2.2092.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a routine transaction related to executive compensation.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for companies with equity-based compensation plans. It reflects ongoing alignment of executive interests with shareholder value through dividend equivalent rights.
Comparison to Industry Standards
- Lemaitre's approach to granting dividend equivalent rights alongside restricted stock units and performance share units is a common practice among publicly traded companies, particularly in the medical device industry.
- Companies like Medtronic, Stryker, and Boston Scientific also utilize similar equity compensation strategies to incentivize and retain key personnel.
- The specific vesting schedules and terms of these awards can vary, but the underlying principle of aligning executive compensation with company performance and shareholder returns remains consistent.
Stakeholder Impact
- The acquisition of dividend equivalent rights by a senior executive aligns their interests with those of shareholders, as the value of these rights is tied to the company's dividend performance.
- This can incentivize the executive to make decisions that benefit the company's long-term financial health and dividend-paying capacity.
Key Dates
| Date | Description |
|---|---|
| 12/2/2020 | Date of grant for restricted stock unit award related to dividend equivalent rights. |
| 12/11/2021 | Date of grant for restricted stock unit award related to dividend equivalent rights. |
| 12/12/2022 | Date of grant for restricted stock unit and Performance Share Unit award related to dividend equivalent rights. |
| 12/8/2023 | Date of grant for restricted stock unit and Performance Share Unit award related to dividend equivalent rights. |
| 12/6/2024 | Date of grant for restricted stock unit award related to dividend equivalent rights. |
| 03/27/2025 | Date of transaction: Acquisition of dividend equivalent rights. |
| 03/31/2025 | Date of signature for the Form 4 filing. |
Keywords
dividend equivalent rights, Lemaitre Vascular Inc., LMAT, Form 4, insider trading, Trent G. Kamke, restricted stock unit, performance share unit, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.